BioAdvance News

Optofluidics Awarded NIH Phase II SBIR

By WebmasterOctober 1, 2014November 1st, 2024No Comments

Optofluidics Awarded NIH Phase II SBIR
Read more here

Previous PostInfrascanner™ Brain Scanner Gets $3.7M-Expands head trauma detection capabilities
Next PostRelmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER